N-(3-methylbutyl)pentanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-(3-methylbutyl)pentanamide
• 化学式: C₁₀H₂₁NO
• 分子量: 171.28
• InChiKey: WYTYGBZOANUUER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20190077752A1

  公开（公告）日：2019-03-14

  The invention relates to novel prodrugs or conjugates of the general formula (Ia) in which cytotoxic drugs, for example kinesin spindle protein inhibitors, are masked with legumain-cleavable groups and hence release the drug, and to the use of these prodrugs or conjugates for treatment and/or prevention of diseases, and to the use of these prodrugs or conjugates for production of medicaments for treatment and/or prevention of diseases, especially of hyperproliferative and/or angiogenic disorders, for example cancers.

  该发明涉及通式(Ia)的新型前药或结合物，其中细胞毒性药物，例如动力蛋白抑制剂，被腿蛋白酶可切割基团掩蔽，从而释放药物，并且涉及使用这些前药或结合物用于治疗和/或预防疾病，以及使用这些前药或结合物用于生产用于治疗和/或预防疾病的药物，特别是治疗和/或预防高增殖和/或血管生成异常的疾病，例如癌症。
• Compounds having estrogen receptor alpha degradation activity and uses thereof
  申请人：ACCUTAR BIOTECHNOLOGY INC.

  公开号：US10450307B2

  公开（公告）日：2019-10-22

  The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of estrogen-related diseases and conditions.

  本公开涉及新型化合物、含有此类化合物的药物组合物及其在预防和治疗雌激素相关疾病和病症中的用途。
• DERIVES D'IMIDAZO-PYRIDINE COMME AGONISTES DU RECEPTEUR DE LA MELANCORTINE
  申请人：IPSEN PHARMA

  公开号：EP1615925B1

  公开（公告）日：2009-05-27
• NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF
  申请人：ACCUTAR BIOTECHNOLOGY INC.

  公开号：US20180208590A1

  公开（公告）日：2018-07-26

  The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of estrogen-related diseases and conditions.
• GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
  申请人：AstraZeneca AB

  公开号：US20190134214A1

  公开（公告）日：2019-05-09

  The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.